We have previously shown that this chimeric peptide is capable of penetrating cells, strongly inhibiting PKC activity, blocking early cell signalling and proliferation, and being able to inhibit Jurkat (T-ALL) and REH (B-ALL) cell growth [29]. This evidence concerns the gene PRRT2 and acute lymphoblastic leukemia.